DeVilbiss Healthcare Sponsors Clinical Trial Confirming the
Effectiveness of SmartFlex™ Technology
SOMERSET, PA – July 5, 2011 – DeVilbiss Healthcare recently sponsored a randomized,
double-blind, crossover clinical study which confirmed the effectiveness of DeVilbiss SmartFlex
Technology, a new exhalation pressure relief solution to enhance patient comfort.
Positive Airway Pressure (PAP) represents the gold standard in the treatment of Obstructive
Sleep Apnea (OSA). In recent years, pressure modification has become accepted as an
important feature improving patients’ comfort and compliance. However, there has been some
speculation that excessive pressure relief may compromise the effectiveness of therapy.
The study confirmed SmartFlex Technology to be equally effective to standard Auto-PAP therapy
in that respiratory events and oxygen saturation during sleep were normalized among the
participants. In addition, treatment with SmartFlex showed a lower leak rate, which likely
contributes to the greater subject acceptance rates. As expected, both modalities resulted in
improved daytime alertness, but improved daytime energy levels, ability to relax and nocturnal
sleep were also demonstrated with SmartFlex Technology.
The study included 28 patients with a recent diagnosis of OSA who agreed to participate in the
research study. Patients were randomly assigned to Auto-PAP (with or without SmartFlex) for two
weeks and were then switched for continued therapy for an additional two weeks. While all
participants experienced treatment with and without SmartFlex, both participants and researchers
were blinded to the assignment of SmartFlex.
The study results were presented at the Associated Professional Sleep Society’s 2011 SLEEP
Conference and Exhibition in Minneapolis by the Principal Investigator of the study, Dr. Leon
Rosenthal, M.D. of Sleep Medicine Associates of Texas, P.A.
“Patient comfort and acceptance of therapy is critical to establishing an adherent patient,” said
Mike Marcinek, VP of Sales & Marketing – Sleep Solutions at DeVilbiss Healthcare. “We are very
excited to see that there was improvement in sleep, relaxation and lower leak rates while on
SmartFlex. With the objective clinical results appearing to show parity between the two therapies,
there is a tremendous amount of subjective data currently being analyzed. We are excited to
review all the findings with the goal of continuing to provide optimal solutions to patients.”
DeVilbiss SmartFlex Technology provides three pressure relief drops and six rounding settings to
ease inhale and exhale transitions. The SmartFlex transitions can be adjusted with DeVilbiss’
patented Flow Rounding™ Technology to make the pressure drop and the corresponding
increase feel even more natural to each patient. SmartFlex Technology is available exclusively
on the DeVilbiss IntelliPAP® AutoAdjust® and IntelliPAP Standard Plus PAP Systems.
Dr. Rosenthal has been involved in the field of Sleep Medicine for over 20 years. Throughout his
career, he has been involved in patient care, education and research. Dr. Rosenthal’s
contributions to the field include over 95 publications in Sleep Medicine, Otolaryngology,
Psychiatry and Pulmonary Medicine journals and books. He has served in both the Sleep
Research Society (SRS) and the American Academy of Sleep Medicine (AASM) in various roles.
He has been a previous Publications Chair for the SRS and chair of the International Affairs
Committee for the AASM.